Connecticut 2023 Regular Session

Connecticut House Bill HB06696 Compare Versions

Version 1 (Old)

Version 2 (New)

Old	New		Differences
1	1
2	2
3		-	LCO \\PRDFS1\HCOUSERS\BARRYJN\WS\2023HB-06696-R01-
4		-	HB.docx
5		-	1 of 4
	3	+	LCO No. 4255 1 of 5
6	4
7		-	General Assembly ~~Substitute~~ Bill No. 6696
	5	+	General Assembly Raised Bill No. 6696
8	6		January Session, 2023
	7	+	LCO No. 4255
	8	+
	9	+
	10	+	Referred to Committee on GENERAL LAW
	11	+
	12	+
	13	+	Introduced by:
	14	+	(GL)
	15	+
9	16
10	17
11	18
12	19		AN ACT CONCERNING THE OPIOID SETTLEMENT FUND AND
13	20		PERSONAL OPIOID DRUG DEACTIVATION AND DISPOSAL
14	21		PRODUCTS.
15	22		Be it enacted by the Senate and House of Representatives in General
16	23		Assembly convened:
17	24
18	25		Section 1. (NEW) (Effective July 1, 2023) (a) For the purposes of this 1
19	26		section: 2
20	27		(1) "Dispense" has the same meaning as provided in section 21a-240 3
21	28		of the general statutes; 4
22	29		(2) "Opioid drug" has the same meaning as provided in section 20-5
23	30		14o of the general statutes; 6
24	31		(3) "Personal opioid drug deactivation and disposal product" means 7
25	32		a product that is designed for personal use and enables a patient to 8
26	33		permanently deactivate and destroy an opioid drug; 9
27		-	(4) "Pharmacist" has the same meaning as provided in section 21a-10
28		-	240 of the general statutes; and 11
29		-	(5) "Pharmacy" has the same meaning as provided in section 21a-240 12
	34	+	(4) "Pharmacist" has the same meaning as provided in section 21a-240 10
	35	+	of the general statutes; and 11
	36	+	(5) "Pharmacy" has the same meaning as provided in section 21a-240 12 Raised Bill No. 6696
	37	+
	38	+
	39	+
	40	+	LCO No. 4255 2 of 5
	41	+
30	42		of the general statutes. 13
31	43		(b) (1) Except as provided in subdivision (2) of this subsection, each 14
32	44		pharmacist who dispenses an opioid drug to a patient in this state shall 15
33		-	provide to the patient, at the time such pharmacist dispenses such 16 Substitute Bill No. 6696
	45	+	provide to the patient, at the time such pharmacist dispenses such drug 16
	46	+	to such patient, a personal opioid drug deactivation and disposal 17
	47	+	product. No pharmacy or pharmacist shall charge any fee to, or impose 18
	48	+	any cost on, any patient for a personal opioid drug deactivation and 19
	49	+	disposal product that a pharmacist provides to a patient pursuant to this 20
	50	+	subdivision. 21
	51	+	(2) Any pharmacy or pharmacist may seek reimbursement from the 22
	52	+	Opioid Settlement Advisory Committee established pursuant to section 23
	53	+	17a-674d of the general statutes for documented expenses incurred by 24
	54	+	such pharmacy or pharmacist in providing personal opioid drug 25
	55	+	deactivation and disposal products to patients pursuant to subdivision 26
	56	+	(1) of this subsection. No such pharmacy or pharmacist shall be required 27
	57	+	to bear any documented expense for providing personal opioid drug 28
	58	+	deactivation and disposal products to patients pursuant to subdivision 29
	59	+	(1) of this subsection and, if there are insufficient funds in the Opioid 30
	60	+	Settlement Fund established in section 17a-674c of the general statutes, 31
	61	+	as amended by this act, to cover such documented expenses or such 32
	62	+	funds are otherwise unavailable, no pharmacist shall be required to 33
	63	+	dispense a personal opioid drug deactivation and disposal product 34
	64	+	pursuant to subdivision (1) of this subsection. 35
	65	+	(c) The Commissioner of Consumer Protection may adopt 36
	66	+	regulations, in accordance with the provisions of chapter 54 of the 37
	67	+	general statutes, to implement the provisions of this section. 38
	68	+	Sec. 2. Subsection (e) of section 17a-674c of the general statutes is 39
	69	+	repealed and the following is substituted in lieu thereof (Effective July 1, 40
	70	+	2023): 41
	71	+	(e) Moneys in the fund shall be spent only for the following substance 42
	72	+	use disorder abatement purposes, in accordance with the controlling 43
	73	+	judgment, consent decree or settlement, as confirmed by the Attorney 44 Raised Bill No. 6696
34	74
35	75
36		-	LCO {\\PRDFS1\HCOUSERS\BARRYJN\WS\2023HB-06696-
37		-	R01-HB.docx }
38		-	2 of 4
39	76
40		-	drug to such patient, a personal opioid drug deactivation and disposal 17
41		-	product. No pharmacy or pharmacist shall charge any fee to, or 18
42		-	impose any cost on, any patient for a personal opioid drug 19
43		-	deactivation and disposal product that a pharmacist provides to a 20
44		-	patient pursuant to this subdivision. 21
45		-	(2) Any pharmacy or pharmacist may seek reimbursement from the 22
46		-	Opioid Settlement Advisory Committee established pursuant to 23
47		-	section 17a-674d of the general statutes for documented expenses 24
48		-	incurred by such pharmacy or pharmacist in providing personal 25
49		-	opioid drug deactivation and disposal products to patients pursuant to 26
50		-	subdivision (1) of this subsection. No such pharmacy or pharmacist 27
51		-	shall be required to bear any documented expense for providing 28
52		-	personal opioid drug deactivation and disposal products to patients 29
53		-	pursuant to subdivision (1) of this subsection and, if there are 30
54		-	insufficient funds in the Opioid Settlement Fund established in section 31
55		-	17a-674c of the general statutes, as amended by this act, to cover such 32
56		-	documented expenses or such funds are otherwise unavailable, no 33
57		-	pharmacist shall be required to provide a personal opioid drug 34
58		-	deactivation and disposal product pursuant to subdivision (1) of this 35
59		-	subsection. 36
60		-	(c) The Commissioner of Consumer Protection may adopt 37
61		-	regulations, in accordance with the provisions of chapter 54 of the 38
62		-	general statutes, to implement the provisions of this section. 39
63		-	Sec. 2. Subsection (e) of section 17a-674c of the general statutes is 40
64		-	repealed and the following is substituted in lieu thereof (Effective July 41
65		-	1, 2023): 42
66		-	(e) Moneys in the fund shall be spent only for the following 43
67		-	substance use disorder abatement purposes, in accordance with the 44
68		-	controlling judgment, consent decree or settlement, as confirmed by 45
69		-	the Attorney General's review of such judgment, consent decree or 46
70		-	settlement and upon the approval of the committee and the Secretary 47
71		-	of the Office of Policy and Management: 48 Substitute Bill No. 6696
	77	+	LCO No. 4255 3 of 5
	78	+
	79	+	General's review of such judgment, consent decree or settlement and 45
	80	+	upon the approval of the committee and the Secretary of the Office of 46
	81	+	Policy and Management: 47
	82	+	(1) State-wide, regional or community substance use disorder needs 48
	83	+	assessments to identify structural gaps and needs to inform 49
	84	+	expenditures from the fund; 50
	85	+	(2) Infrastructure required for evidence-based substance use disorder 51
	86	+	prevention, treatment, recovery or harm reduction programs, services 52
	87	+	and supports; 53
	88	+	(3) Programs, services, supports and resources for evidence-based 54
	89	+	substance use disorder prevention, treatment, recovery or harm 55
	90	+	reduction; 56
	91	+	(4) Evidence-informed substance use disorder prevention, treatment, 57
	92	+	recovery or harm reduction pilot programs or demonstration studies 58
	93	+	that are not evidence-based, but are approved by the committee as an 59
	94	+	appropriate use of moneys for a limited period of time as specified by 60
	95	+	the committee, provided the committee shall assess whether the 61
	96	+	evidence supports funding such programs or studies or whether it 62
	97	+	provides a basis for funding such programs or studies with an 63
	98	+	expectation of creating an evidence base for such programs and studies; 64
	99	+	(5) Evaluation of effectiveness and outcomes reporting for substance 65
	100	+	use disorder abatement infrastructure, programs, services, supports and 66
	101	+	resources for which moneys from the fund have been disbursed, 67
	102	+	including, but not limited to, impact on access to harm reduction 68
	103	+	services or treatment for substance use disorders or reduction in drug-69
	104	+	related mortality; 70
	105	+	(6) One or more publicly available data interfaces managed by the 71
	106	+	commissioner to aggregate, track and report data on (A) substance use 72
	107	+	disorders, overdoses and drug-related harms, (B) spending 73
	108	+	recommendations, plans and reports, and (C) outcomes of programs, 74
	109	+	services, supports and resources for which moneys from the fund were 75 Raised Bill No. 6696
72	110
73	111
74		-	LCO {\\PRDFS1\HCOUSERS\BARRYJN\WS\2023HB-06696-
75		-	R01-HB.docx }
76		-	3 of 4
77	112
78		-	(1) State-wide, regional or community substance use disorder needs 49
79		-	assessments to identify structural gaps and needs to inform 50
80		-	expenditures from the fund; 51
81		-	(2) Infrastructure required for evidence-based substance use 52
82		-	disorder prevention, treatment, recovery or harm reduction programs, 53
83		-	services and supports; 54
84		-	(3) Programs, services, supports and resources for evidence-based 55
85		-	substance use disorder prevention, treatment, recovery or harm 56
86		-	reduction; 57
87		-	(4) Evidence-informed substance use disorder prevention, 58
88		-	treatment, recovery or harm reduction pilot programs or 59
89		-	demonstration studies that are not evidence-based, but are approved 60
90		-	by the committee as an appropriate use of moneys for a limited period 61
91		-	of time as specified by the committee, provided the committee shall 62
92		-	assess whether the evidence supports funding such programs or 63
93		-	studies or whether it provides a basis for funding such programs or 64
94		-	studies with an expectation of creating an evidence base for such 65
95		-	programs and studies; 66
96		-	(5) Evaluation of effectiveness and outcomes reporting for substance 67
97		-	use disorder abatement infrastructure, programs, services, supports 68
98		-	and resources for which moneys from the fund have been disbursed, 69
99		-	including, but not limited to, impact on access to harm reduction 70
100		-	services or treatment for substance use disorders or reduction in drug-71
101		-	related mortality; 72
102		-	(6) One or more publicly available data interfaces managed by the 73
103		-	commissioner to aggregate, track and report data on (A) substance use 74
104		-	disorders, overdoses and drug-related harms, (B) spending 75
105		-	recommendations, plans and reports, and (C) outcomes of programs, 76
106		-	services, supports and resources for which moneys from the fund were 77
107		-	disbursed; 78
108		-	(7) Research on opioid abatement, including, but not limited to, 79 Substitute Bill No. 6696
	113	+	LCO No. 4255 4 of 5
109	114
110		-
111		-	LCO {\\PRDFS1\HCOUSERS\BARRYJN\WS\2023HB-06696-
112		-	R01-HB.docx }
113		-	4 of 4
114		-
115		-	development of evidence-based treatment, barriers to treatment, 80
116		-	nonopioid treatment of chronic pain and harm reduction, supply-side 81
117		-	enforcement; 82
118		-	(8) Documented expenses incurred in administering and staffing the 83
119		-	fund and the committee, and expenses, including, but not limited to, 84
120		-	legal fees, incurred by the state or any municipality in securing 85
121		-	settlement proceeds, deposited in the fund as permitted by the 86
122		-	controlling judgment, consent decree or settlement; 87
123		-	(9) Documented expenses associated with managing, investing and 88
124		-	disbursing moneys in the fund; [and] 89
125		-	(10) Documented expenses, including legal fees, incurred by the 90
126		-	state or any municipality in securing settlement proceeds deposited in 91
127		-	the fund to the extent such expenses are not otherwise reimbursed 92
128		-	pursuant to a fee agreement provided for by the controlling judgment, 93
129		-	consent decree or settlement; and 94
130		-	(11) Documented expenses incurred by pharmacies and pharmacists 95
131		-	in providing personal opioid drug deactivation and disposal products 96
132		-	to patients pursuant to section 1 of this act. 97
	115	+	disbursed; 76
	116	+	(7) Research on opioid abatement, including, but not limited to, 77
	117	+	development of evidence-based treatment, barriers to treatment, 78
	118	+	nonopioid treatment of chronic pain and harm reduction, supply-side 79
	119	+	enforcement; 80
	120	+	(8) Documented expenses incurred in administering and staffing the 81
	121	+	fund and the committee, and expenses, including, but not limited to, 82
	122	+	legal fees, incurred by the state or any municipality in securing 83
	123	+	settlement proceeds, deposited in the fund as permitted by the 84
	124	+	controlling judgment, consent decree or settlement; 85
	125	+	(9) Documented expenses associated with managing, investing and 86
	126	+	disbursing moneys in the fund; [and] 87
	127	+	(10) Documented expenses, including legal fees, incurred by the state 88
	128	+	or any municipality in securing settlement proceeds deposited in the 89
	129	+	fund to the extent such expenses are not otherwise reimbursed pursuant 90
	130	+	to a fee agreement provided for by the controlling judgment, consent 91
	131	+	decree or settlement; and 92
	132	+	(11) Documented expenses incurred by pharmacies and pharmacists 93
	133	+	in providing personal opioid drug deactivation and disposal products 94
	134	+	to patients pursuant to section 1 of this act. 95
133	135		This act shall take effect as follows and shall amend the following
134	136		sections:
135	137
136	138		Section 1 July 1, 2023 New section
137	139		Sec. 2 July 1, 2023 17a-674c(e)
138	140
139		-	Statement of Legislative Commissioners:
140		-	In Section 1(b)(2), "dispense" was changed to "provide" for internal
141		-	consistency.
	141	+	Statement of Purpose:
	142	+	To require pharmacists to provide personal opioid drug deactivation
	143	+	and disposal products to certain patients, and dedicate moneys
	144	+	deposited in the Opioid Settlement Fund to reimburse pharmacies and
	145	+	pharmacists for expenses incurred in providing such products to
	146	+	patients. Raised Bill No. 6696
142	147
143		-	GL Joint Favorable Subst. -LCO
	148	+
	149	+
	150	+	LCO No. 4255 5 of 5
	151	+
	152	+	[Proposed deletions are enclosed in brackets. Proposed additions are indicated by underline, except
	153	+	that when the entire text of a bill or resolution or a section of a bill or resolution is new, it is not
	154	+	underlined.]
144	155